All resolutions submitted for a vote at today's Combined General Meeting were approved
Launch of the largest pivotal clinical trial for CER-001 in sepsis, the 3rd cause of death worldwide
Progress in regulatory and manufacturing phases toward approval of CER-001 for LCAT deficiency
Financial visibility through the end of 2028 following the raising of up to €33 million
Focus on leveraging and optimizing a unique scientific apoA-I platform
TOULOUSE, France & FULLERTON, Calif., June 30, 2026--(BUSINESS WIRE)--Regulatory News:
ABIONYX Pharma (FR0012616852 – ABNX – eligible for the PEA PME program), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I-based technology platform, today provided an update on the Combined General Meeting held at the company's headquarters and the new phase of development beginning on June 30, 2026.
At the Combined General Meeting, all resolutions presented by the Board of Directors were adopted. ABIONYX Pharma thanks all shareholders who were present, represented, or voted by mail for their commitment and support during this General Meeting. The minutes of the General Meeting, as well as the voting results by resolution, will be available on the Company's website in the "General Meetings" section.
Having secured the necessary resources for the development of its priority programs through a recent strategic financing transaction, the Company is entering a phase in which value creation will rely primarily on clinical execution, the quality of the data generated, and the progressive monetization of its scientific platform.
Financial Resources to Support All Strategic Objectives
Following the success of its recently completed financing round, the Company has secured funding totaling up to €33 million. This strengthened financial position provides a solid foundation for pursuing all of the Company's strategic objectives and allows it to fully focus its resources on the development of its priority programs:
the clinical development of CER-001 for sepsis; initiation of a pivotal Phase 2b clinical trial by the end of 2026, with the first results expected in the first half of 2028,
market access for CER-001 in LCAT deficiency; validation of the production of two GMP batches in 2027 for submission of a marketing authorization application to the EMA by early 2028,
the development of new scientific, technological, and industrial partnerships.
A Strategy Fully Focused on Execution